Clinical Trials

 

 

Clinical Trials
Disease Target Title of Study Phase Study Drugs

Adjuvant Prostate XRP6976J

SANOFI-AVENTIS
A Multicenter, Open Label, Randomized Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy (Eligard-Leuprolide Acetate) in combination with Taxotere Administered every 3 weeks versus Hormonal Therapy along Versus Deferred Therapy Followed by the same Therapeutic Options in Patients with Prostate Cancer at High Risk of Relapse after Radical Prostatectomy

III

Taxotere
Eligard
Leuprolide

Metastatic Prostate
D9902B

DENDREON
A Randomized, Double Blind, Placebo Controlled, Phase III Trial of Immunotherapy with Autologous Antigen Presenting Cells Loaded with PA2024 (Provenge, APC8015) in Men with Metastic Androgen Independent Prostatic Adenocarcinoma

III

Provenge
APC8015

Metastatic Prostate
PB01

DENDREON
An Open Label, Single Arm Trial of Immunotherapy with Autologous Presenting Cells Loaded with PA2024 (APC8015) for Subjects with Objective Disease Progression and Disease Related Pain on D9902B

 

Provenge
APC8015F

Metastatic Prostate
CALGB 90401

CALGB
A Randomized Double Blinded Placebo Controlled Phase III Trial Comparing Docetaxel and Prednisone with and without Bevacizumab in Men with Hormone Refractory Prostate Cancer

III

Docetaxel
Prednisone
Bevacizumab

Metastatic
Prostate
G0034

CELL GENESYS
A phase III Randomized, Open Label Study of Docetaxel in Combination with CG-1940 versus Docetaxel and Prednisone in Taxane Naïve Patients with Metastatic Hormone Refractory Prostate Cancer with Pain

III

Docetaxel
Prednisone
CG-41104

Prostate
E5803

Phase II Trial of GW572016 in Patients with Recurrent Prostate Cancer as Evident by a Rising PSA

   

Prostate
AR140006

A Randomized Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5mg Administered Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer

   

Prostate
S0000

Selenium and Vitamin E Cancer Prevention Trial (SELECT)

   

Prostate
S0437

Prostate Cancer Prevention Trial (PCPT) Companion Long Term Follow Up Study  for Men Diagnosed with Prostate Cancer

   

Prostate

GUILFORD PHARMACEUTICALS
Phase II Multi-Center, Randomized, Double-blind, Placebo-Controlled, 3-Arm,12 month study to evaluate the effects of GPI 1485 on erectile function in patients undergoing bilateral nerve sparing radical retropubic prostatectomies for prostates carcinoma

   

Prostate

SANOFI-SYNTHELABO, INC.
Prospective, Observational Registry of the Management of Men with Prostate Cancer and a Rising PSA Following Definitive Surgical or Radiological Treatment of the Primary Tumor:  PCA Registry COMPARE (Comprehensive, Observational, Multicenter Prostate Adenocarcinoma Registry)

   

Adjuvant Renal Cell Ca
C 100-12 PII

ANTIGENICS
A Multi Center, Randomized Phase III Study of Adjuvant Oncophage versus Observation in Patients with High Risk of Recurrence after Surgical Treatment of Renal Cell Carcinoma

III

Oncophage
HSPPC – 96

Metastatic Renal Cell Ca
E8802

ECOG
Phase II Trial of Doxorubicin and Gemcitabine in Metastatic Renal Cell Carcinoma with Sarcomatoid Features

II

Doxorubicin
Gemcitabine

Metastatic
Renal Cell Ca
BAY 11868

BAYER
Open Label, Non-comparative Treatment Protocol for the use of Sorafenib in Patients with Advanced Renal Cell Carcinoma

EAP

Sorafenib

Metastatic Renal Cell Ca
CALGB 90206

CALGB
A Randomized Phase III Trial of Interferon alfa 2B or Interferon Alfa 2B plus Bevacizumab in Patients with Advanced Renal Cell Carcinoma

III

Interferon Alfa
Bevacizumab

Renal Cell Carcinoma
E2805

A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma

A Phase II Study of Sorafenib in Patients with Metastatic Renal Cell Carcinoma

Phase II Study of Interleukin-2 and Bevacizumab in Patients with Progressive Metastatic Renal Cell Carcinoma

   

Urothelial Carcinoma
E-1804

Phase II Trial of Sorafenib (BAY43-9006) (IND 69896; NSC 724772) in Patients with Advanced Urothelial Cancer

   

Bladder

PHOTOCURE ASA
A Randomized, Comparative, Controlled Phase III, Multi-Center Study of Hexvix Flourescence Cystoscopy and White Light Cystoscopy in the Detection of Papillary Bladder Cancer and the Early Recurrence Rate in Patients with Bladder Cancer

   
 


best-hospitals-cardiology    high-performing-indicator-heartfailure    high-performing-indicator-heartbypass     HG_Americas_50_Best_Award_Image_2014      HG_Americas_100_Best_Stroke_Care_Award_Image_2014        HG_Americas_100_Best_Pulmonary_Care_Award_Image_2014     red-bulllgbt      tkc_homepagelogo-2
 


Translation service provided by Google. HackensackUMC is not responsible for the accuracy of translation or any other
aspect of service provided by the GoogleTranslate tool. Users should not make medical decisions without first consulting
with their physician.
 
Site Map|Privacy Policy|Media Center
©2016 Hackensack University Medical Center. All rights reserved.
close (X)